Montanide ISA-51

DRUG10 trials

Conditions

Adult Soft Tissue SarcomaAdvanced Renal Cell CancerBone CancerBreast CancerColon CancerColorectal CancerExtraocular Extension MelanomaEye Cancer

Phase 1

Vaccine Therapy in Treating Patients With Metastatic Cancer

CompletedNCT00020267

National Cancer Institute (NCI)Adult Soft Tissue Sarcoma, Bone Cancer, Breast Cancer +8

Start: 2000-07-31Updated: 2024-03-04

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

TerminatedNCT02425306

Craig L Slingluff, JrMelanoma

Start: 2015-05-12End: 2018-01-08Updated: 2023-10-30

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

NCT02429440

University Hospital TuebingenAdvanced Renal Cell Cancer, Renal Cell Cancer

Start: 2005-05-31End: 2018-06-30Updated: 2017-08-17

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

NCT02452307

University Hospital TuebingenRecurrent Prostate Cancer

Start: 2004-04-30End: 2017-10-31Updated: 2017-08-17

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

CompletedNCT03617328

Craig L Slingluff, JrMelanoma

Start: 2018-11-13End: 2024-01-19Updated: 2024-02-06

Phase 2

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

CompletedNCT00001832

National Cancer Institute (NCI)Melanoma, Neoplasm Metastasis

Start: 1999-08-31End: 2010-05-31Updated: 2012-12-21

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

CompletedNCT00273910

National Cancer Institute (NCI)High-Risk Melanoma

Start: 2006-01-31End: 2010-05-31Updated: 2012-10-19

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

CompletedNCT00019396

National Cancer Institute (NCI)Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage IV Melanoma +1

Start: 1998-02-28End: 2007-03-31Updated: 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

CompletedNCT00020475

National Cancer Institute (NCI)Extraocular Extension Melanoma, Recurrent Intraocular Melanoma

Start: 2001-02-28End: 2007-03-31Updated: 2024-03-04

Unknown Phase

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

CompletedNCT00912574

University of VirginiaMelanoma

Start: 2004-06-30Updated: 2009-06-03

Related Papers

Adjuvant polypeptide vaccines for high-risk uveal melanoma.

Journal of Clinical Oncology2023-06-013 citations

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

Journal for ImmunoTherapy of Cancer2020-04-0132 citations

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

2017-10-0417 citations

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

2012-05-03170 citations